Getlabs, a provider for at-home diagnostics, will be adding GRAIL’s Galleri multi-cancer early detection test to its list of test offerings. Getlabs will facilitate the sample collection process for the Galleri test by bringing the convenience of at-home blood draws to patients, eliminating the need for visits to clinics, and reducing barriers to testing.
GRAIL’s Galleri test is a significant advancement in multi-cancer early detection screening, according to Getlabs. By analyzing fragments of cell-free DNA (cfDNA) in a simple blood draw, the Galleri test can help screen for many of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others. The current screening paradigm screens for one cancer at a time and only covers five cancers types in the U.S.: breast, colon, cervical, prostate, and, in high-risk adults, lung. This approach is insufficient in substantially reducing cancer-related deaths since it fails to cover the majority of cancers, says Getlabs.
Further reading: GRAIL’s Multi-Cancer Early Detection Test Gets Added to Insurance Plan
This collaboration aims to make early cancer detection more accessible to all, including those with limited access to healthcare facilities or facing logistical challenges, thereby addressing the shortcomings of the current screening paradigm.
“Partnering with GRAIL allows us to extend the reach of early cancer detection and make it even more convenient for patients to prioritize their health,” says Kyle Michelson, CEO, Getlabs. “By leveraging our expertise in at-home diagnostic collections, we can greatly expand access to critical cancer screening services. Our partnership with GRAIL represents a step forward in saving lives through early cancer detection.”
